Cambiotics initiates first human clinical trial focused on PFAS reduction in firefighters with occupational PFAS exposure
COPENHAGEN, Denmark, Nov. 3, 2026 /PRNewswire/ -- Cambiotics ApS ("Cambiotics"), the company developing beneficial bacteria designed to support the natural elimination of unwanted compounds, such as per- and polyfluoroalkyl substances (PFAS, known as "forever chemicals"), announced today...
Covered in this story
Call it yourself
No calls on $NOV yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on NOV →Dalsna Finance is currently tracking 116 stories mentioning NOV, the earliest published 25 Oct 2026.
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.